Radiopharm Theranostics (NASDAQ:RADX) Shares Down 1.8% – Should You Sell?

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) fell 1.8% during trading on Monday. The company traded as low as $1.10 and last traded at $1.11. 9,582 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 63,648 shares. The stock had previously closed at $1.13.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $11.00.

Radiopharm Theranostics Stock Performance

The stock has a 50 day simple moving average of $2.00 and a two-hundred day simple moving average of $3.50.

Radiopharm Theranostics (NASDAQ:RADX) last issued its earnings results on Friday, July 31st. The company reported ($0.81) earnings per share (EPS) for the quarter. The business had revenue of $0.49 million during the quarter. Equities analysts forecast that Radiopharm Theranostics Limited – Sponsored ADR will post -3.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Radiopharm Theranostics stock. Hsbc Holdings PLC bought a new position in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 191,624 shares of the company’s stock, valued at approximately $1,007,000. Hsbc Holdings PLC owned 1.62% of Radiopharm Theranostics at the end of the most recent reporting period.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics Limited is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its approach combines targeted molecules with radioactive isotopes to help identify tumors through medical imaging and deliver radiation directly to cancer cells.

The company’s pipeline includes diagnostic and therapeutic programs based on peptides, small molecules and antibodies. These programs are designed to address cancers with significant unmet medical needs, including solid tumors and other difficult-to-treat malignancies.